Medicines for Smoking Cessation: Global Markets
NEW YORK, Oct. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Medicines for Smoking Cessation: Global Markets
http://www.reportlinker.com/p01658945/Medicines-for-Smoking-Cessation-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
STUDY GOALS AND OBJECTIVES
This BCC Research report analyzes the global trends in smoking cessation. Public health departments and national regulatory agencies are working to create awareness on the health hazards of smoking. Their efforts are to educate, counsel and prevent people from smoking. Smoking cessation medications are used to help patients cope with the withdrawal symptoms of smoking and nicotine dependence and assist them in quitting smoking completely.The objective of this study is to understand current market trends, future prospects and opportunities in nicotine dependence treatments. The report will assess the role of smoking cessation medicines in improving the quit rate. It will bring out the key result areas of smoking cessation medicines and will address the areas that need improvement.
REASONS FOR DOING THE STUDY
Reducing the prevalence of smoking is a national agenda of many nations, including emerging markets. This development provides an opportunity to manufacturers and marketers of smoking cessation medicines to expand organically. The study will help in understanding the length and breadth of the market as well as initiate strategies.
SCOPE OF REPORT
The report covers developed and emerging markets in order to help readers understand:• The current state of the smoking cessation market and the key markets for its future development.• New technologies that will influence the development of smoking cessation products.• Market drivers and threats for the smoking cessation medicine industry.• Major regional trends in the global smoking cessation market.• Competitive analysis of the market.• Branded versus generic, and over-the-counter versus prescription for nicotine replacements, non-nicotine and antidepressants.
INTENDED AUDIENCE
• Executives of pharmaceutical companies who are currently marketing smoking cessation aids.• Executives of companies that provide third-party manufacturing and development facilities for smoking cessation medications.• Manufacturers of gum base, resins, alkaloids and other raw materials for the manufacturing of nicotine replacement therapies.• Developers of novel nicotine delivery systems.• Tobacco companies that intend to enter the tobacco transformation market.• Entrepreneurs, management consultants, and merger and acquisition (M&A) consultants.• Financial institutions, venture capitalists and angel investors.• Manufacturers and exporters of alternate smoking cessation aids.• Government agencies, public health departments and organizations working in tobacco prevention and control.
INFORMATION SOURCES
The information and analysis presented in this BCC Research report are based on firsthand information from primary executives, product managers and clinical specialists; background information obtained from various government, business, medical journal and trade magazines; and statistical data from organizations such as the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Centers for Disease Control (CDC), The Tobacco Atlas and others working in public health and tobacco control.Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as to formulate market projections. All market data pertain to the manufacturer's level. Data are expressed in 2012 U.S. dollars. The base year was 2012. Historical data are provided for 2011 and forecast data are provided for 2013 and 2018. Historical, base year and forecast data are provided for each market segment and sub-segment. Market shares are provided for each market segment for the base year of 2012.
ANALYST CREDENTIALS
Anand Gijare has been authoring business reports as his main focus for the last five years. His domain expertise lays in the pharmaceutical, IT and telecom fields. He has a diploma in Financial Management, a PGDM in marketing and a Bachelor of Science degree in Chemistry.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC's home page, located at www.bccresearch.com, enables readers to:• Examine BCC's complete catalog of Market Research Reports and place direct orders.• Subscribe to any of BCC's many industry newsletters.• Read announcements of recently published reports and newly launched newsletters.• Register for BCC's well-known conferences.• Request additional information on any BCC product.• Take advantage of special offers.
REPORT HIGHLIGHTS
This report provides:• An overview of the global market for medicines used to quit smoking, which help in coping with nicotine withdrawal symptoms developed after a long-term addiction to tobacco.• Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.• Discussion of the history and current state of smoking cessation methods, worldwide trends in smoking, and mechanisms of actions, such as nicotine replacement therapy, nicotine receptor partial agonist, and antidepressants.• A list of pipeline products and an in-depth focus on promising pipeline candidates, as well current patents and new applications.• Comprehensive company profiles of major players in the industry.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2STUDY GOALS AND OBJECTIVES 2REASONS FOR DOING THE STUDY 2SCOPE OF REPORT 2INTENDED AUDIENCE 2INFORMATION SOURCES 3ANALYST CREDENTIALS 3RELATED REPORTS 3BCC ONLINE SERVICES 4DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SUMMARY TABLE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BYREGION, THROUGH 2018 ($ MILLIONS) 8SUMMARY FIGURE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BYREGION, 2011-2018 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 12
SMOKING AND HEALTH HAZARDS 12CURRENT TRENDS IN THE TOBACCO INDUSTRY 13HEALTH HAZARDS OF SMOKING 14METHODS OF SMOKING CESSATION 16SMOKING CESSATION WITHOUT ASSISTANCE 16SMOKING CESSATION WITH EXPERT INTERVENTIONS 18SMOKING CESSATION WITH MEDICATION 18HEALTH BENEFITS OF SMOKING CESSATION 18TABLE 1 BENEFITS OF SMOKING CESSATION 19TRENDS IN SMOKING CESSATION 20ROLE OF NICOTINE 21FIGURE 1 NICOTINE MOLECULE: 3-[(2S)-1-METHYLPYRROLIDINE-2-YL]PYRIDINE 21UNDERSTANDING NICOTINE ADDICTION 22TABLE 2 GENERAL CRITERIA FOR DRUG DEPENDENCE 23UNDERSTANDING NICOTINE ABSORPTION MECHANISM 24UNDERSTANDING WITHDRAWAL SYMPTOMS OF NICOTINE 25
CHAPTER 4 SMOKING CESSATION MEDICINES 28
TABLE 3 CLASSIFICATION OF SMOKING CESSATION MEDICINES BASED ON MODEOF ACTION 29NICOTINE REPLACEMENT THERAPY 29TABLE 4 CLASSIFICATION OF NICOTINE REPLACEMENT THERAPY BASED ON DRUGDELIVERY SYSTEM 29NICOTINE REPLACEMENT THERAPY: ORAL MUCOSA DELIVERY SYSTEM 30Nicotine Gum 30TABLE 5 NICOTINE GUM DOSAGES AND SCHEDULES 30Key Brands 31TABLE 6 KEY BRANDS AND MARKETERS OF NICOTINE GUMS 32Nicotine Lozenges 32TABLE 7 NICOTINE LOZENGE DOSAGE AND SCHEDULE 32TABLE 8 KEY BRANDS AND MARKETERS OF NICOTINE LOZENGES 33Nicotine Tablets 33TABLE 9 KEY BRANDS AND MARKETERS OF NICOTINE TABLETS 34Nicotine Inhalers 34TABLE 10 KEY BRANDS AND MARKETERS OF NICOTINE INHALERS 34Nicotine Mouth Sprays 35TABLE 11 KEY BRANDS AND MARKETERS OF NICOTINE MOUTH SPRAYS 35NICOTINE REPLACEMENT THERAPY: TRANSDERMAL DELIVERY SYSTEM 35Nicotine Patches 35TABLE 12 NICOTINE PATCH DOSAGE AND SCHEDULE 36TABLE 13 KEY BRANDS AND MARKETERS OF NICOTINE PATCHES 37NICOTINE REPLACEMENT THERAPY: NASAL DELIVERY SYSTEM 37Nicotine Nasal Sprays 37TABLE 14 KEY BRANDS AND MARKETERS OF NICOTINE NASAL SPRAYS 37NON-NICOTINE THERAPIES 38CHANTIX/CHAMPIX (VARENICLINE TARTRATE) 38Mechanism of Action 38Marketing 38TABLE 15 CHANTIX/CHAMPIX SALES REVENUE, 2007-2012 ($ MILLIONS) 39Zyban (bupropion HCl) 39R&D IN SMOKING CESSATION MEDICINES 40DEVELOPMENTS IN THE PIPELINE (NICOTINE REPLACEMENT THERAPY) 40NICOTINE VACCINES 40TABLE 16 NICOTINE VACCINES IN DEVELOPMENT PHASE AS OF JANUARY 2013 41NICOTINE ORALLY DISSOLVABLE FILMS 41VERY LOW NICOTINE CIGARETTES 42CYTISINE (TABEX) 42DEVELOPMENTS IN THE PIPELINE (NON-NICOTINE THERAPY) 43TABLE 17 DEVELOPMENTS IN THE PIPELINE (NON-NICOTINE) 43GSK598809 SELECTIVE D3 RECEPTOR ANTAGONIST 44D-CYCLOSERINE 44TABLE 18 CLINICAL TRIALS OF D-CYCLOSERINE 44EVT 302 44SELEGILINE 45NALMEFENE 45
CHAPTER 5 THE GLOBAL SMOKING CESSATION MEDICINE MARKET 47
SMOKING CESSATION MARKET REVENUE, 2012 47SMOKING CESSATION MEDICINE MARKET FORECAST, 2013-2018 47TABLE 19 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, THROUGH2018 ($ MILLIONS) 48FIGURE 2 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, 2011-2018($ MILLIONS) 48GLOBAL MARKET FORECAST BY CLASSIFICATION OF SMOKING CESSATIONMEDICINES, 2013-2018 49TABLE 20 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BYCLASSIFICATION, THROUGH 2018 ($ MILLIONS) 49FIGURE 3 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BYCLASSIFICATION, 2011-2018 ($ MILLIONS) 50GLOBAL MARKET FORECAST BY TYPE OF SALES, 2013-2018 50TABLE 21 GLOBAL SMOKING CESSATION MEDICINES BY TYPE OF SALES 50TABLE 22 SMOKING CESSATION MEDICINES FORECAST BY TYPE OF SALES,THROUGH 2018 ($ MILLIONS) 51FIGURE 4 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY TYPE OFSALES, 2011-2018 ($ MILLIONS) 51GLOBAL SMOKING CESSATION MEDICINE MARKET FORECAST BY CATEGORY,2013-2018 52TABLE 23 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY,THROUGH 2018 ($ MILLIONS) 53FIGURE 5 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY,2011-2018 ($ MILLIONS) 53GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY CATEGORY,2013-2018 55TABLE 24 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BYCATEGORY, THROUGH 2018 ($ MILLIONS) 56FIGURE 6 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BYCATEGORY, 2011-2018 ($ MILLIONS) 56
CHAPTER 6 LEADING MARKETS FOR SMOKING CESSATION MEDICINES 59
GLOBAL MARKET FORECAST BY REGION FOR SMOKING CESSATION MEDICINES,2013-2018 59EMERGING MARKETS ARE NEW TARGET MARKETS FOR SMOKINGCESSATION, THROUGH 2018 59Quit Rates are High in Developed Countries 59Decrease in Smoking Rates Have Reached Saturation Point inDeveloped Markets 60Smoking Rates are Increasing in Developing Markets 60STRATEGIC INITIATIVES TO INCREASE SMOKING CESSATION INDEVELOPING COUNTRIES 60Developing and Poor Countries Sign WHO FCTC Treaty 61WHO FCTC Progress Report 2012 61TABLE 25 ARTICLES REPORTING HIGHEST IMPLEMENTATION RATES: 2012 WHOFCTC PROGRESS REPORT (%) 62TABLE 26 ARTICLES REPORTING MODERATE IMPLEMENTATION RATES: 2012 WHOFCTC PROGRESS REPORT (%) 62TABLE 27 ARTICLES REPORTING LOWEST IMPLEMENTATION RATES: 2012 WHOFCTC PROGRESS REPORT (%) 63FIGURE 7 GLOBAL IMPLEMENTATION OF ARTICLES: 2012 FCTC REPORT (%) 63TABLE 28 GLOBAL IMPLEMENTATION OF FCTC ARTICLES: 2012 REPORT 64Implementation of Article 14 in 2012 66TABLE 29 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC, 2012 67TABLE 30 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION,THROUGH 2018 ($ MILLIONS) 69FIGURE 8 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION,2011-2018 ($ MILLIONS) 69THE U.S.: SMOKING CESSATION MARKET 70CIGARETTE SMOKING DECLINES IN THE U.S. 71THE U.S. SMOKING CESSATION MEDICINE MARKET 71TABLE 31 SMOKING CESSATION BRANDS IN THE U.S. MARKET, 2012 72NEW ENTRANTS EYE THE U.S. MARKET 72THE U.S.: SMOKING CESSATION MARKET REVENUE, 2012 73THE U.S.: MARKET FORECAST FOR SMOKING CESSATION MEDICINES,2013-2018 73TABLE 32 SMOKING CESSATION MEDICINE MARKET IN THE U.S., THROUGH 2018 ($MILLIONS) 73FIGURE 9 SMOKING CESSATION MEDICINE MARKET IN THE U.S., 2011-2018 ($MILLIONS) 73CANADA: SMOKING CESSATION MARKET 74CANADA SMOKING CESSATION MEDICINE MARKET 75TABLE 33 SMOKING CESSATION BRANDS IN CANADA MARKET: 2012 76NEW ENTRANTS IN CANADIAN MARKET 76CANADA: SMOKING CESSATION MARKET REVENUE 2012 76CANADA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES,2013-2018 77TABLE 34 SMOKING CESSATION MEDICINE MARKET IN CANADA, THROUGH 2018 ($MILLIONS) 77EUROPE: SMOKING CESSATION MEDICINE MARKET 77TABLE 35 SMOKING CESSATION BRANDS IN EUROPEAN MARKET: 2012 78EUROPE: SMOKING CESSATION MARKET REVENUE, 2012 78EUROPE: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018 79TABLE 36 SMOKING CESSATION MEDICINE MARKET IN EUROPE, THROUGH 2018 ($MILLIONS) 79FIGURE 10 SMOKING CESSATION MEDICINE MARKET IN EUROPE, 2011-2018 ($MILLIONS) 79THE U.K.: SMOKING CESSATION MEDICINE MARKET 80TOBACCO INDUSTRY IN THE U.K. 80SMOKING BANS AND REGULATING NICOTINE PRODUCTS 80THE U.K.: SMOKING CESSATION MARKET REVENUE, 2012 81TABLE 37 SMOKING CESSATION BRANDS IN THE U.K. MARKET: 2012 81THE U.K.: MARKET FORECAST FOR SMOKING CESSATION MEDICINES,2013-2018 82TABLE 38 SMOKING CESSATION MEDICINE MARKET IN THE U.K., THROUGH 2018 ($MILLIONS) 82FIGURE 11 SMOKING CESSATION MEDICINE MARKET IN THE U.K., 2011-2018 ($MILLIONS) 82FRANCE: SMOKING CESSATION MEDICINE MARKET 83FRANCE: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018 84TABLE 39 SMOKING CESSATION MEDICINE MARKET IN FRANCE, THROUGH 2018 ($MILLIONS) 84FIGURE 12 SMOKING CESSATION MEDICINE MARKET IN FRANCE, 2011-2018 ($MILLIONS) 84OTHER PROMISING EUROPEAN MARKETS 85GERMANY HAS LOW POTENTIAL FOR SMOKING CESSATION MEDICATION 85ASIA PACIFIC: SMOKING CESSATION MEDICINE MARKET 85TABLE 40 SMOKING CESSATION MEDICINE MARKET IN ASIA PACIFIC, THROUGH2018 ($ MILLIONS) 86AUSTRALIA: SMOKING CESSATION MEDICINE MARKET 87TABLE 41 SMOKING CESSATION BRANDS IN AUSTRALIA MARKET: 2012 88AUSTRALIA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES,2013-2018 88TABLE 42 SMOKING CESSATION MEDICINE MARKET IN AUSTRALIA, THROUGH 2018($ MILLIONS) 88NEW ZEALAND: SMOKING CESSATION MEDICINE MARKET 89TABLE 43 SMOKING CESSATION BRANDS IN NEW ZEALAND MARKET: 2012 90JAPAN: SMOKING CESSATION MEDICINE MARKET 91JAPAN: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018 92EMERGING MARKETS FOR SMOKING CESSATION MEDICINES 92TABLE 44 SMOKING CESSATION MEDICINE MARKET IN EMERGING MARKETS,THROUGH 2018 ($ MILLIONS) 93EMERGING MARKETS: MARKET FORECAST FOR SMOKING CESSATIONMEDICINES, 2013-2018 93CHINA: SMOKING CESSATION MEDICINE MARKET 93SMOKING PREVALENCE AND TOBACCO CONTROL INITIATIVES 93SMOKING CESSATION MEDICINE MARKET IN CHINA 95CHINA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018 95CHINA: MARKET POTENTIAL COULD BE TAPPED THROUGH COPDTREATMENT 95INDIA: SMOKING CESSATION MEDICINE MARKET 96TOBACCO CONTROL INITIATIVES IN INDIA 96SMOKING CESSATION MEDICINE MARKET IN INDIA 97TABLE 45 SMOKING CESSATION BRANDS IN INDIAN MARKET: 2012 98GENERIC BUPROPION HCL LEADS INDIAN MARKET FOR SMOKINGCESSATION 98INDIA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018 99TABLE 46 SMOKING CESSATION MEDICINE MARKET IN INDIA, THROUGH 2018 ($MILLIONS) 99BRAZIL: SMOKING CESSATION MEDICINE MARKET 99SMOKING CESSATION MEDICINE MARKET IN BRAZIL 100TABLE 47 SMOKING CESSATION BRANDS IN BRAZILIAN MARKET, 2012 100BRAZIL: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018 101TABLE 48 SMOKING CESSATION MEDICINE MARKET IN BRAZIL, THROUGH 2018 ($MILLIONS) 101
CHAPTER 7 SMOKING CESSATION INDUSTRY AND MARKET ANALYSES 103
GLOBAL MARKET FOR SMOKING CESSATION MEDICINES 104PESTLE ANALYSIS 104Political and Legal Interventions Influence Markets 104TABLE 49 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY (%) 106Socioeconomic Factors 106TABLE 50 PROJECTED GLOBAL CAUSE OF DEATH (%) 108TABLE 51 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES ($BILLIONS) 108Technology Developments 108FIGURE 13 GLOBAL STUDIES ON TOBACCO DEPENDENCE AND SMOKINGCESSATION, BY REGION (NO. OF ONGOING STUDIES) 109TABLE 52 SWOT ANALYSIS OF SMOKING CESSATION MEDICINES 110COMPETITIVE ANALYSIS AND BENCHMARKING 111TOBACCO TRANSFORMATION STRATEGY 111DIFFERENTIATION BETWEEN SMOKING CESSATION MEDICINES ANDALTERNATIVES TO CIGARETTES 112TABLE 53 COMPARING SMOKING CESSATION MEDICINES AND OTHER NICOTINEDELIVERY SYSTEMS 112COLLABORATIONS AND COMBINATIONS 112INDUSTRY OPINION ON FUTURE OF THE SMOKING CESSATION MEDICINEINDUSTRY 113UNTAPPED POTENTIAL OF SMOKING CESSATION MARKET COULD BE $60BILLION 114
CHAPTER 8 COMPANY PROFILES 116
22ND CENTURY GROUP INC. 116ACTAVIS, INC. 116ALKALON A/S 117BIOTA PHARMACEUTICALS, INC. 117BIOTIE THERAPIES CORP. 117BOEHRINGER INGELHEIM GMBH 118CELTIC PHARMA MANAGEMENT L.P. 118CIPLA LTD. 118CYTOS BIOTECHNOLOGY AG 119EVOTEC AG 119FERTIN PHARMA A/S 119GENTECH HEALTHCARE 120GLAXOSMITHKLINE PLC 120JOHNSON & JOHNSON 121MCNEIL CONSUMER HEALTHCARE 121NICONOVUM AB 121NOVARTIS INTERNATIONAL AG 122PERRIGO CO. 122PFIZER INC. 122PIERRE FABRE PHARMACEUTICALS INC. 123LABORATOIRES PIERRE FABRE 123PSYCOREMEDIES 123REVOLYMER (U.K.) LTD. 124SANOFI 124SOMAXON PHARMACEUTICALS INC. 124SOPHARMA AD 125SUN PHARMACEUTICAL INDUSTRIES LTD. 125TAISHO PHARMACEUTICAL HOLDINGS 125TAKEDA PHARMACEUTICALS LTD. 126TARGACEPT, INC. 126WALGREENS 126ZENARA PHARMACEUTICALS 127
LIST OF TABLES
SUMMARY TABLE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY
REGION, THROUGH 2018 ($ MILLIONS) 8
TABLE 1 BENEFITS OF SMOKING CESSATION 19
TABLE 2 GENERAL CRITERIA FOR DRUG DEPENDENCE 23
TABLE 3 CLASSIFICATION OF SMOKING CESSATION MEDICINES BASED ON MODE OF
ACTION 29
TABLE 4 CLASSIFICATION OF NICOTINE REPLACEMENT THERAPY BASED ON DRUG
DELIVERY SYSTEM 29
TABLE 5 NICOTINE GUM DOSAGES AND SCHEDULES 30
TABLE 6 KEY BRANDS AND MARKETERS OF NICOTINE GUMS 32
TABLE 7 NICOTINE LOZENGE DOSAGE AND SCHEDULE 32
TABLE 8 KEY BRANDS AND MARKETERS OF NICOTINE LOZENGES 33
TABLE 9 KEY BRANDS AND MARKETERS OF NICOTINE TABLETS 34
TABLE 10 KEY BRANDS AND MARKETERS OF NICOTINE INHALERS 34
TABLE 11 KEY BRANDS AND MARKETERS OF NICOTINE MOUTH SPRAYS 35
TABLE 12 NICOTINE PATCH DOSAGE AND SCHEDULE 36
TABLE 13 KEY BRANDS AND MARKETERS OF NICOTINE PATCHES 37
TABLE 14 KEY BRANDS AND MARKETERS OF NICOTINE NASAL SPRAYS 37
TABLE 15 CHANTIX/CHAMPIX SALES REVENUE, 2007-2012 ($ MILLIONS) 39
TABLE 16 NICOTINE VACCINES IN DEVELOPMENT PHASE AS OF JANUARY 2013 41
TABLE 17 DEVELOPMENTS IN THE PIPELINE (NON-NICOTINE) 43
TABLE 18 CLINICAL TRIALS OF D-CYCLOSERINE 44
TABLE 19 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, THROUGH
2018 ($ MILLIONS) 48
TABLE 20 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY
CLASSIFICATION, THROUGH 2018 ($ MILLIONS) 49
TABLE 21 GLOBAL SMOKING CESSATION MEDICINES BY TYPE OF SALES 50
TABLE 22 SMOKING CESSATION MEDICINES FORECAST BY TYPE OF SALES,
THROUGH 2018 ($ MILLIONS) 51
TABLE 23 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY,
THROUGH 2018 ($ MILLIONS) 53
TABLE 24 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY
CATEGORY, THROUGH 2018 ($ MILLIONS) 56
TABLE 25 ARTICLES REPORTING HIGHEST IMPLEMENTATION RATES: 2012 WHO
FCTC PROGRESS REPORT (%) 62
TABLE 26 ARTICLES REPORTING MODERATE IMPLEMENTATION RATES: 2012 WHO
FCTC PROGRESS REPORT (%) 62
TABLE 27 ARTICLES REPORTING LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC
PROGRESS REPORT (%) 63
TABLE 28 GLOBAL IMPLEMENTATION OF FCTC ARTICLES: 2012 REPORT 64
TABLE 29 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC, 2012 67
TABLE 30 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION,
THROUGH 2018 ($ MILLIONS) 69
TABLE 31 SMOKING CESSATION BRANDS IN THE U.S. MARKET, 2012 72
TABLE 32 SMOKING CESSATION MEDICINE MARKET IN THE U.S., THROUGH 2018 ($
MILLIONS) 73
TABLE 33 SMOKING CESSATION BRANDS IN CANADA MARKET: 2012 76
TABLE 34 SMOKING CESSATION MEDICINE MARKET IN CANADA, THROUGH 2018 ($
MILLIONS) 77
TABLE 35 SMOKING CESSATION BRANDS IN EUROPEAN MARKET: 2012 78
TABLE 36 SMOKING CESSATION MEDICINE MARKET IN EUROPE, THROUGH 2018 ($
MILLIONS) 79
TABLE 37 SMOKING CESSATION BRANDS IN THE U.K. MARKET: 2012 81
TABLE 38 SMOKING CESSATION MEDICINE MARKET IN THE U.K., THROUGH 2018 ($
MILLIONS) 82
TABLE 39 SMOKING CESSATION MEDICINE MARKET IN FRANCE, THROUGH 2018 ($
MILLIONS) 84
TABLE 40 SMOKING CESSATION MEDICINE MARKET IN ASIA PACIFIC, THROUGH 2018
($ MILLIONS) 86
TABLE 41 SMOKING CESSATION BRANDS IN AUSTRALIA MARKET: 2012 88
TABLE 42 SMOKING CESSATION MEDICINE MARKET IN AUSTRALIA, THROUGH 2018
($ MILLIONS) 88
TABLE 43 SMOKING CESSATION BRANDS IN NEW ZEALAND MARKET: 2012 90
TABLE 44 SMOKING CESSATION MEDICINE MARKET IN EMERGING MARKETS,
THROUGH 2018 ($ MILLIONS) 93
TABLE 45 SMOKING CESSATION BRANDS IN INDIAN MARKET: 2012 98
TABLE 46 SMOKING CESSATION MEDICINE MARKET IN INDIA, THROUGH 2018 ($
MILLIONS) 99
TABLE 47 SMOKING CESSATION BRANDS IN BRAZILIAN MARKET, 2012 100
TABLE 48 SMOKING CESSATION MEDICINE MARKET IN BRAZIL, THROUGH 2018 ($
MILLIONS) 101
TABLE 49 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY (%) 106
TABLE 50 PROJECTED GLOBAL CAUSE OF DEATH (%) 108
TABLE 51 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES ($
BILLIONS) 108
TABLE 52 SWOT ANALYSIS OF SMOKING CESSATION MEDICINES 110
TABLE 53 COMPARING SMOKING CESSATION MEDICINES AND OTHER NICOTINE
DELIVERY SYSTEMS 112
LIST OF FIGURES
SUMMARY FIGURE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY
REGION, 2011-2018 ($ MILLIONS) 8
FIGURE 1 NICOTINE MOLECULE: 3-[(2S)-1-METHYLPYRROLIDINE-2-YL]PYRIDINE 21
FIGURE 2 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, 2011-2018
($ MILLIONS) 48
FIGURE 3 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY
CLASSIFICATION, 2011-2018 ($ MILLIONS) 50
FIGURE 4 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY TYPE OF
SALES, 2011-2018 ($ MILLIONS) 51
FIGURE 5 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY,
2011-2018 ($ MILLIONS) 53
FIGURE 6 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY
CATEGORY, 2011-2018 ($ MILLIONS) 56
FIGURE 7 GLOBAL IMPLEMENTATION OF ARTICLES: 2012 FCTC REPORT (%) 63
FIGURE 8 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION,
2011-2018 ($ MILLIONS) 69
FIGURE 9 SMOKING CESSATION MEDICINE MARKET IN THE U.S., 2011-2018 ($
MILLIONS) 73
FIGURE 10 SMOKING CESSATION MEDICINE MARKET IN EUROPE, 2011-2018 ($
MILLIONS) 79
FIGURE 11 SMOKING CESSATION MEDICINE MARKET IN THE U.K., 2011-2018 ($
MILLIONS) 82
FIGURE 12 SMOKING CESSATION MEDICINE MARKET IN FRANCE, 2011-2018 ($
MILLIONS) 84
FIGURE 13 GLOBAL STUDIES ON TOBACCO DEPENDENCE AND SMOKING CESSATION,
BY REGION (NO. OF ONGOING STUDIES) 109
To order this report: Medicines for Smoking Cessation: Global Markets http://www.reportlinker.com/p01658945/Medicines-for-Smoking-Cessation-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
__________________________
Contact Clare: [email protected]: (339)-368-6001Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article